Table 3. Observed reductions in Schistosoma infection intensity in selected field studies.

Study [citation]	Country Location	Study Size	Diagnosed with	Local Pre-treatment Prevalence	Two Dose Interval	Follow up interval	One Dose-Any Intensity	One Dose-Light Infections	One Dose-Heavy Infections	Two Doses-Any Intensity	Two Doses-Light Infections	Two Doses-Heavy Infections
							Reported reduction in Schistosoma mansoni infection intensity
Barakat, 2010s [12]	Egypt	588	1 stool, KK	44%	4 weeks	4 weeks	71%	34%	87%	74%	34%	89%
Utzinger, 2000s [21]	Cote d'Ivoire	253	4 stools KK	77%	5 weeks (60 mg/40 mg)	4 weeks	80%			89%
Black, 2009a [13]	Kenya	178	3 stools KK	83%	6 weeks	4–6 weeks	83% (62–91%)
Picquet, 1998c [18]	Senegal	113	1 stool, KK	87%	6 weeks	4 weeks	71%	30%	88%	88%	56%	96%
Kabatereine 2003c [14]	Uganda	617	3 stools KK	92%	6 weeks	6 weeks	98%			99.6%
							Reported reduction in S. haematobium infection intensity
Midzi, 2008s [16]	Zimbabwe	675	3 urines, filtration	51%	6 weeks	4 months	94%
Mduluza, 2001s [15]	Zimbabwe	595	3 urines, filtration	52%	8 weeks	8 weeks	96%			92%
Tchuem-Tchuente, 2004s [20]	Cameroon	515	2 urines, filtration	42%	3 weeks	6 weeks	98%	98%	99%	99%	98%	99.7%
N'goran, 2003s [17]	Cote d'Ivoire	354	4 urines, filtration	77%	4 weeks	3 weeks				97%
Sacko, 2009s - [19] Selingue	Mali	256	3 urines, filtration	87%	2 weeks	3 months	99%			99%
Sacko, 2009s - [19] Koulikoro	Mali	300	3 urines, filtration	95%	2 weeks	3 months	98%			99%

^sStudy based on school age participants only;

^aStudy based on adults only;

^cCommunity-based study.